Capienda is developing an advanced bioanalytical technology to accelerate drug discovery in the pharmaceutical industry.
Capienda’s drug delivery technology is designed to target disease-relevant cells (while avoiding normal cells) and engages previously un-druggable targets. Program for anti-inflammatory therapy is Patent Pending with ownership assigned to Capienda Biotech, LLC.
Mark A. Bernard and Souvenir D. Tachado. COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES, US Provisional Patent Application No. 62/651,621 (filed April 2, 2018).